{"id":"NCT02041533","sponsor":"Bristol-Myers Squibb","briefTitle":"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)","officialTitle":"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-27","primaryCompletion":"2016-07-01","completion":"2022-05-27","firstPosted":"2014-01-22","resultsPosted":"2017-07-26","lastUpdate":"2023-03-02"},"enrollment":541,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Stage IV or Recurrent Non-Small Cell Lung Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558","MDX-1106"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemzar"]},{"type":"DRUG","name":"Cisplatin","otherNames":["Platinol"]},{"type":"DRUG","name":"Carboplatin","otherNames":["Paraplatin"]},{"type":"DRUG","name":"Paclitaxel","otherNames":["Taxol"]},{"type":"DRUG","name":"Pemetrexed","otherNames":["Alimta"]}],"arms":[{"label":"Arm A: Nivolumab subjects","type":"EXPERIMENTAL"},{"label":"Arm B: Investigator's Choice Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy","primaryOutcome":{"measure":"Progression-Free Survival in Participants With PD-L1 Expression >= 5%","timeFrame":"From date of randomization until date of documented tumor progression (assessed up to August 2016, approximately 28 months)","effectByArm":[{"arm":"Nivolumab","deltaMin":4.21,"sd":null},{"arm":"Investigator Choice of Chemotherapy","deltaMin":5.88,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2511"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":141,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Finland","France","Germany","Greece","Hungary","Italy","Japan","Mexico","Netherlands","Poland","Romania","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["38383458","28636851"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm","https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"]},"adverseEventsSummary":{"seriousAny":{"events":195,"n":267},"commonTop":["Fatigue","Nausea","Anaemia","Decreased appetite","Diarrhoea"]}}